South Africa's controversial Health Minister Manto Tshabalala-Msimang has announced the next step in her stated objective of regulating health care costs via price controls, with the launch of new legislation. For the drug industry, the good news is that Ms Tshabalala-Msimang has widened her targets from drugs to other health care costs, according to the Business Day. In particular, she has blamed collusion and unjustified price rises in the past year, to justify intervention.
Opposition members of the National Assembly argued that the government's approach is counterproductive. Ruth Rabinowitz (Inkatha Freedom Party) warned that the Minister's new legislative proposals would contradict her objective of making health care more accessible and affordable.
Sandy Kalyan, of the main opposition party, the Democratic Alliance, said that, "rather than capping the private industry, you should free up the health market to encourage competition and that will bring down prices."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze